Enveric Biosciences, Inc. (ENVB) 10-Year Financial Performance & Capital Metrics

ENVB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutEnveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Show more

Revenue $0
EBITDA -$9M +42.1%
Net Income -$10M -55272.4%
EPS (Diluted) -228.48 -135.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -539.57% -273098.0%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 76.7% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-16498.45%

ROCE

10Y Avg-133.73%

5Y Avg-219%

3Y Avg-276.65%

Latest-542.79%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	15.98M	36.15M	48.59M	43M	39.91M	0	0	0	0	0
Revenue Growth %	-	1.26%	0.34%	-0.12%	-0.07%	-1%	-	-	-	-
Cost of Goods Sold+	10.23M	29.61M	38.36M	34.01M	31.76M	120.87K	681.61K	435.2K	408.03K	337.49K
COGS % of Revenue	0.64%	0.82%	0.79%	0.79%	0.8%	-	-	-	-	-
Gross Profit+	5.75M	6.54M	10.24M	8.98M	8.15M	-120.87K	-681.61K	-435.2K	-408.03K	-337.49K
Gross Margin %	0.36%	0.18%	0.21%	0.21%	0.2%	-	-	-	-	-
Gross Profit Growth %	-	0.14%	0.57%	-0.12%	-0.09%	-1.01%	-4.64%	0.36%	0.06%	0.17%
Operating Expenses+	5.97M	10.33M	21.73M	13.7M	14.48M	5.5M	25.26M	19.53M	16.04M	9.29M
OpEx % of Revenue	0.37%	0.29%	0.45%	0.32%	0.36%	-	-	-	-	-
Selling, General & Admin	5.81M	8.97M	18.51M	10.79M	12.21M	5.32M	20.47M	11.5M	8.79M	6.45M
SG&A % of Revenue	0.36%	0.25%	0.38%	0.25%	0.31%	-	-	-	-	-
Research & Development	0	0	0	0	0	174.08K	4.79M	8.03M	7.25M	2.84M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	157.94K	-394.21K	1.08M	88.16K	2.27M	0	0	0	0	0
Operating Income+	-1.87M	-5.38M	-11.97M	-7.15M	-6.32M	-5.62M	-25.94M	-19.96M	-16.45M	-9.63M
Operating Margin %	-0.12%	-0.15%	-0.25%	-0.17%	-0.16%	-	-	-	-	-
Operating Income Growth %	-56.01%	-1.88%	-1.23%	0.4%	0.11%	0.11%	-3.62%	0.23%	0.18%	0.41%
EBITDA+	-1.71M	-4.02M	-8.75M	-4.24M	-4.06M	-5.5M	-25.26M	-19.53M	-16.04M	-9.29M
EBITDA Margin %	-0.11%	-0.11%	-0.18%	-0.1%	-0.1%	-	-	-	-	-
EBITDA Growth %	-51.2%	-1.35%	-1.18%	0.52%	0.04%	-0.35%	-3.6%	0.23%	0.18%	0.42%
D&A (Non-Cash Add-back)	157.94K	1.36M	3.22M	2.9M	2.27M	120.87K	681.61K	435.2K	408.03K	337.49K
EBIT	-704.06K	-5.77M	-10.89M	-9.82M	-4.52M	-6.42M	-56.42M	-19.95M	-17.26M	-9.57M
Net Interest Income+	-148.55K	-751.07K	-575.04K	-729.9K	-691.14K	-444.81K	-10.31K	-5.24K	-3.71K	219
Interest Income	89.92K	0	0	0	0	445	10	5	0	219
Interest Expense	238.47K	751.07K	575.04K	729.9K	691.14K	445.25K	10.32K	5.25K	3.71K	0
Other Income/Expense	-1.23M	-2.73M	-11.47M	-10.55M	1.11M	-1.25M	-30.49M	4.05K	-814.38K	66.21K
Pretax Income+	-2.02M	-6.53M	-11.47M	-10.55M	-5.22M	-6.86M	-56.43M	-19.96M	-17.26M	-9.57M
Pretax Margin %	-0.13%	-0.18%	-0.24%	-0.25%	-0.13%	-	-	-	-	-
Income Tax+	-128.46K	-3.75M	-2.39M	6.35M	388.66K	0	-7.45M	-1.49M	28.91K	8.93K
Effective Tax Rate %	0.94%	0.43%	0.79%	1.6%	1.07%	1%	0.87%	0.93%	0%	1%
Net Income+	-1.89M	-2.78M	-9.07M	-16.9M	-5.6M	-6.86M	-48.98M	-18.5M	-17.29K	-9.57M
Net Margin %	-0.12%	-0.08%	-0.19%	-0.39%	-0.14%	-	-	-	-	-
Net Income Growth %	-55.2%	-0.47%	-2.26%	-0.86%	0.67%	-0.22%	-6.13%	0.62%	1%	-552.73%
Net Income (Continuing)	-2.52M	-2.78M	-9.07M	-16.9M	-5.6M	-6.86M	-48.98M	-18.47M	-17.29M	-9.57M
Discontinued Operations	0	0	0	0	0	0	0	0	19.04K	0
Minority Interest	0	3.38K	0	0	0	0	0	885.03K	0	0
EPS (Diluted)+	-10220.28	-12770.04	-36347.76	-42616.68	-2543.88	-666.00	-1244.28	-156.00	-97.08	-228.48
EPS Growth %	-3.43%	-0.25%	-1.85%	-0.17%	0.94%	0.74%	-0.87%	0.87%	0.38%	-1.35%
EPS (Basic)	-10272.72	-12770.04	-36347.76	-42616.68	-2543.88	-666.00	-1244.28	-87.72	-97.08	-228.48
Diluted Shares Outstanding	185	218	250	396	2.2K	9.59K	39.36K	173.19K	179.92K	41.91K
Basic Shares Outstanding	198	218	250	396	2.2K	9.59K	39.36K	210.63K	210.63K	41.91K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.18M	10.06M	14.64M	10.06M	7.6M	2.28M	17.74M	18.43M	3.58M	2.73M
Cash & Short-Term Investments	1.96M	1.46M	4.88M	1.37M	431.4K	1.58M	17.36M	17.72M	2.29M	2.24M
Cash Only	1.88M	1.38M	4.88M	1.37M	431.4K	1.58M	17.36M	17.72M	2.29M	2.24M
Short-Term Investments	82.91K	82.91K	0	0	0	0	0	0	0	0
Accounts Receivable	4.87M	8.06M	8.84M	7.87M	6.38M	0	0	0	224.61K	0
Days Sales Outstanding	111.31	81.39	66.39	66.82	58.38	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	343.81K	542.24K	924.27K	818.6K	718.53K	700.71K	0	159.78K	567.6K	0
Total Non-Current Assets+	6.66M	29.44M	37.55M	19.58M	17.41M	1.82M	8.98M	1.12M	718.31K	347.96K
Property, Plant & Equipment	73.07K	100.24K	95.05K	58.89K	83.13K	0	470.73K	741.3K	507.38K	305.78K
Fixed Asset Turnover	218.66x	360.59x	511.25x	730.12x	480.16x	-	-	-	-	-
Goodwill	3.47M	17.09M	21.9M	13.73M	13.73M	0	1.59M	0	0	0
Intangible Assets	3.11M	8.76M	9.47M	5.78M	3.58M	1.82M	6.92M	379.69K	210.93K	42.18K
Long-Term Investments	0	0	-6.18M	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	6.18M	0	0	0	0	0	0	0
Total Assets+	13.83M	39.51M	52.2M	29.64M	25.01M	4.1M	26.72M	19.55M	4.3M	3.08M
Asset Turnover	1.15x	0.91x	0.93x	1.45x	1.60x	-	-	-	-	-
Asset Growth %	2719.73%	1.86%	0.32%	-0.43%	-0.16%	-0.84%	5.52%	-0.27%	-0.78%	-0.28%
Total Current Liabilities+	8.58M	12.71M	30.37M	14.69M	14.38M	681.25K	2.08M	4M	2.34M	1.49M
Accounts Payable	2.6M	5.13M	5.32M	4.38M	4.7M	681.25K	683.39K	463.27K	1.22M	521.75K
Days Payables Outstanding	92.71	63.25	50.67	46.98	53.97	2.06K	365.95	388.55	1.09K	564.28
Short-Term Debt	1.24M	3.49M	4.8M	5.21M	4.88M	0	0	0	0	0
Deferred Revenue (Current)	44.84K	0	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	3K	564.24K	20.24M	3.8M	737.79K	0	0	1.76M	350.72K	3.09K
Current Ratio	0.84x	0.79x	0.48x	0.68x	0.53x	3.35x	8.51x	4.61x	1.53x	1.84x
Quick Ratio	0.84x	0.79x	0.48x	0.68x	0.53x	3.35x	8.51x	4.61x	1.53x	1.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	15.14M	2.38M	4.19M	0	0	2.33M	0	0	0
Long-Term Debt	5M	1.54M	2.38M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	68.86K	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	13.6M	0	4.19M	0	0	2.26M	0	0	0
Total Liabilities	13.58M	27.84M	32.75M	18.88M	14.38M	681.25K	4.41M	4M	2.34M	1.49M
Total Debt+	6.24M	5.03M	7.18M	5.21M	4.88M	0	176.3K	63.82K	0	0
Net Debt	4.36M	3.65M	2.3M	3.84M	4.45M	-1.58M	-17.18M	-17.66M	-2.29M	-2.24M
Debt / Equity	24.12x	0.43x	0.37x	0.48x	0.46x	-	0.01x	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.84x	-7.16x	-20.82x	-9.79x	-9.15x	-12.62x	-2514.98x	-3802.90x	-4435.93x	-
Total Equity+	258.53K	11.66M	19.44M	10.76M	10.62M	3.42M	22.31M	15.56M	1.96M	1.59M
Equity Growth %	67.79%	44.11%	0.67%	-0.45%	-0.01%	-0.68%	5.53%	-0.3%	-0.87%	-0.19%
Book Value per Share	1397.48	53503.22	77779.20	27169.44	4821.40	356.20	566.69	89.83	10.87	38.01
Total Shareholders' Equity	258.53K	11.66M	19.44M	10.76M	10.62M	3.42M	22.31M	14.67M	1.96M	1.59M
Common Stock	118.74K	138.86K	181.63K	423.29K	25.22K	100.95K	6.52K	20.78K	27.39K	6.78K
Retained Earnings	-1.05M	-3.83M	-15M	-34.48M	-40.51M	-11.76M	-60.74M	-79.21M	-96.5M	-106.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-7.43K	36.88K	87K	60.01K	-181.28K	-30.8K	-536.73K	-569.75K	-594.52K
Minority Interest	0	3.38K	0	0	0	0	0	885.03K	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.67M	-2.7M	-2.74M	-2.57M	-647.86K	-3.89M	-11.46M	-17.15M	-14.09M	-7.73M
Operating CF Margin %	-0.23%	-0.07%	-0.06%	-0.06%	-0.02%	-	-	-	-	-
Operating CF Growth %	-84.06%	0.26%	-0.01%	0.06%	0.75%	-5%	-1.95%	-0.5%	0.18%	0.45%
Net Income	-1.89M	-2.78M	-11.16M	-16.9M	-2.41M	-6.86M	-48.98M	-18.47M	-17.29M	-9.57M
Depreciation & Amortization	157.94K	1.36M	3.22M	2.9M	0	120.87K	681.61K	435.2K	408.03K	337.49K
Stock-Based Compensation	0	1.46M	7.08M	1.25M	0	1.98M	12.6M	2.62M	2.15M	1.56M
Deferred Taxes	0	-3.49M	-2.39M	6.35M	0	0	-7.45M	-1.5M	0	0
Other Non-Cash Items	552.62K	528.39K	1.06M	4.86M	738.5K	1.25M	30.51M	-9.3K	813.88K	372.21K
Working Capital Changes	-2.49M	218.45K	-539.78K	-1.03M	1.02M	-369.5K	1.19M	-217.66K	-174.75K	-423.24K
Change in Receivables	-2.3M	-3.19M	-778.54K	967.03K	1.49M	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	3.6M	620.79K	-2.1M	222.68K	0	383.2K	263.69K	-103.85K	-834.63K
Cash from Investing+	-1.51M	-6.59M	-808.88K	-3.64M	0	-44.14K	2.19M	-584.16K	11.67K	0
Capital Expenditures	-1.69M	-3.69M	-4.84K	0	0	-44.14K	-864.72K	-584.16K	-5.18K	0
CapEx % of Revenue	0.11%	0.1%	0%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-2.9B	-804.04K	6.42K	0	0	-675	-958.04K	16.85K	0
Cash from Financing+	6.24M	8.8M	7.05M	2.69M	560K	5.53M	24.9M	18.18M	-1.34M	7.67M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-2.09B	-2.09T	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	3.38K	2.09B	-1.66M	22K	3.37M	3.29M	958.04K	-291.08K	4.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.36M	-6.39M	-2.75M	-2.57M	-647.86K	-3.93M	-12.32M	-17.73M	-14.1M	-7.73M
FCF Margin %	-0.34%	-0.18%	-0.06%	-0.06%	-0.02%	-	-	-	-	-
FCF Growth %	-123.12%	-0.19%	0.57%	0.07%	0.75%	-5.07%	-2.13%	-0.44%	0.2%	0.45%
FCF per Share	-28960.57	-29325.62	-10982.54	-6478.52	-294.08	-410.15	-313.05	-102.38	-78.37	-184.36
FCF Conversion (FCF/Net Income)	1.94x	0.97x	0.30x	0.15x	0.12x	0.57x	0.23x	0.93x	815.10x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	9.51K	5K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1484.92%	-46.65%	-58.34%	-111.89%	-52.42%	-97.81%	-380.82%	-97.74%	-0.2%	-539.57%
Return on Invested Capital (ROIC)	-60.9%	-40.49%	-48.45%	-29.5%	-31.98%	-49.83%	-558.88%	-990.44%	-	-
Gross Margin	36%	18.08%	21.07%	20.89%	20.42%	-	-	-	-	-
Net Margin	-11.83%	-7.69%	-18.67%	-39.3%	-14.04%	-	-	-	-	-
Debt / Equity	24.12x	0.43x	0.37x	0.48x	0.46x	-	0.01x	0.00x	-	-
Interest Coverage	-7.84x	-7.16x	-20.82x	-9.79x	-9.15x	-12.62x	-2514.98x	-3802.90x	-4435.93x	-
FCF Conversion	1.94x	0.97x	0.30x	0.15x	0.12x	0.57x	0.23x	0.93x	815.10x	0.81x
Revenue Growth	-	126.24%	34.44%	-11.51%	-7.17%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Enveric Biosciences, Inc. (ENVB) grew revenue by 0.0% over the past year. Growth has been modest.

Enveric Biosciences, Inc. (ENVB) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Enveric Biosciences, Inc. (ENVB) has a return on equity (ROE) of -539.6%. Negative ROE indicates the company is unprofitable.

Enveric Biosciences, Inc. (ENVB) had negative free cash flow of $7.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Enveric Biosciences, Inc. (ENVB) 10-Year Financial Performance & Capital Metrics

ENVB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$9M +42.1%
Net Income -$10M -55272.4%
EPS (Diluted) -228.48 -135.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -539.57% -273098.0%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 76.7% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-16498.45%

ROCE

10Y Avg-133.73%

5Y Avg-219%

3Y Avg-276.65%

Latest-542.79%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	15.98M	36.15M	48.59M	43M	39.91M	0	0	0	0	0
Revenue Growth %	-	1.26%	0.34%	-0.12%	-0.07%	-1%	-	-	-	-
Cost of Goods Sold+	10.23M	29.61M	38.36M	34.01M	31.76M	120.87K	681.61K	435.2K	408.03K	337.49K
COGS % of Revenue	0.64%	0.82%	0.79%	0.79%	0.8%	-	-	-	-	-
Gross Profit+	5.75M	6.54M	10.24M	8.98M	8.15M	-120.87K	-681.61K	-435.2K	-408.03K	-337.49K
Gross Margin %	0.36%	0.18%	0.21%	0.21%	0.2%	-	-	-	-	-
Gross Profit Growth %	-	0.14%	0.57%	-0.12%	-0.09%	-1.01%	-4.64%	0.36%	0.06%	0.17%
Operating Expenses+	5.97M	10.33M	21.73M	13.7M	14.48M	5.5M	25.26M	19.53M	16.04M	9.29M
OpEx % of Revenue	0.37%	0.29%	0.45%	0.32%	0.36%	-	-	-	-	-
Selling, General & Admin	5.81M	8.97M	18.51M	10.79M	12.21M	5.32M	20.47M	11.5M	8.79M	6.45M
SG&A % of Revenue	0.36%	0.25%	0.38%	0.25%	0.31%	-	-	-	-	-
Research & Development	0	0	0	0	0	174.08K	4.79M	8.03M	7.25M	2.84M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	157.94K	-394.21K	1.08M	88.16K	2.27M	0	0	0	0	0
Operating Income+	-1.87M	-5.38M	-11.97M	-7.15M	-6.32M	-5.62M	-25.94M	-19.96M	-16.45M	-9.63M
Operating Margin %	-0.12%	-0.15%	-0.25%	-0.17%	-0.16%	-	-	-	-	-
Operating Income Growth %	-56.01%	-1.88%	-1.23%	0.4%	0.11%	0.11%	-3.62%	0.23%	0.18%	0.41%
EBITDA+	-1.71M	-4.02M	-8.75M	-4.24M	-4.06M	-5.5M	-25.26M	-19.53M	-16.04M	-9.29M
EBITDA Margin %	-0.11%	-0.11%	-0.18%	-0.1%	-0.1%	-	-	-	-	-
EBITDA Growth %	-51.2%	-1.35%	-1.18%	0.52%	0.04%	-0.35%	-3.6%	0.23%	0.18%	0.42%
D&A (Non-Cash Add-back)	157.94K	1.36M	3.22M	2.9M	2.27M	120.87K	681.61K	435.2K	408.03K	337.49K
EBIT	-704.06K	-5.77M	-10.89M	-9.82M	-4.52M	-6.42M	-56.42M	-19.95M	-17.26M	-9.57M
Net Interest Income+	-148.55K	-751.07K	-575.04K	-729.9K	-691.14K	-444.81K	-10.31K	-5.24K	-3.71K	219
Interest Income	89.92K	0	0	0	0	445	10	5	0	219
Interest Expense	238.47K	751.07K	575.04K	729.9K	691.14K	445.25K	10.32K	5.25K	3.71K	0
Other Income/Expense	-1.23M	-2.73M	-11.47M	-10.55M	1.11M	-1.25M	-30.49M	4.05K	-814.38K	66.21K
Pretax Income+	-2.02M	-6.53M	-11.47M	-10.55M	-5.22M	-6.86M	-56.43M	-19.96M	-17.26M	-9.57M
Pretax Margin %	-0.13%	-0.18%	-0.24%	-0.25%	-0.13%	-	-	-	-	-
Income Tax+	-128.46K	-3.75M	-2.39M	6.35M	388.66K	0	-7.45M	-1.49M	28.91K	8.93K
Effective Tax Rate %	0.94%	0.43%	0.79%	1.6%	1.07%	1%	0.87%	0.93%	0%	1%
Net Income+	-1.89M	-2.78M	-9.07M	-16.9M	-5.6M	-6.86M	-48.98M	-18.5M	-17.29K	-9.57M
Net Margin %	-0.12%	-0.08%	-0.19%	-0.39%	-0.14%	-	-	-	-	-
Net Income Growth %	-55.2%	-0.47%	-2.26%	-0.86%	0.67%	-0.22%	-6.13%	0.62%	1%	-552.73%
Net Income (Continuing)	-2.52M	-2.78M	-9.07M	-16.9M	-5.6M	-6.86M	-48.98M	-18.47M	-17.29M	-9.57M
Discontinued Operations	0	0	0	0	0	0	0	0	19.04K	0
Minority Interest	0	3.38K	0	0	0	0	0	885.03K	0	0
EPS (Diluted)+	-10220.28	-12770.04	-36347.76	-42616.68	-2543.88	-666.00	-1244.28	-156.00	-97.08	-228.48
EPS Growth %	-3.43%	-0.25%	-1.85%	-0.17%	0.94%	0.74%	-0.87%	0.87%	0.38%	-1.35%
EPS (Basic)	-10272.72	-12770.04	-36347.76	-42616.68	-2543.88	-666.00	-1244.28	-87.72	-97.08	-228.48
Diluted Shares Outstanding	185	218	250	396	2.2K	9.59K	39.36K	173.19K	179.92K	41.91K
Basic Shares Outstanding	198	218	250	396	2.2K	9.59K	39.36K	210.63K	210.63K	41.91K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.18M	10.06M	14.64M	10.06M	7.6M	2.28M	17.74M	18.43M	3.58M	2.73M
Cash & Short-Term Investments	1.96M	1.46M	4.88M	1.37M	431.4K	1.58M	17.36M	17.72M	2.29M	2.24M
Cash Only	1.88M	1.38M	4.88M	1.37M	431.4K	1.58M	17.36M	17.72M	2.29M	2.24M
Short-Term Investments	82.91K	82.91K	0	0	0	0	0	0	0	0
Accounts Receivable	4.87M	8.06M	8.84M	7.87M	6.38M	0	0	0	224.61K	0
Days Sales Outstanding	111.31	81.39	66.39	66.82	58.38	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	343.81K	542.24K	924.27K	818.6K	718.53K	700.71K	0	159.78K	567.6K	0
Total Non-Current Assets+	6.66M	29.44M	37.55M	19.58M	17.41M	1.82M	8.98M	1.12M	718.31K	347.96K
Property, Plant & Equipment	73.07K	100.24K	95.05K	58.89K	83.13K	0	470.73K	741.3K	507.38K	305.78K
Fixed Asset Turnover	218.66x	360.59x	511.25x	730.12x	480.16x	-	-	-	-	-
Goodwill	3.47M	17.09M	21.9M	13.73M	13.73M	0	1.59M	0	0	0
Intangible Assets	3.11M	8.76M	9.47M	5.78M	3.58M	1.82M	6.92M	379.69K	210.93K	42.18K
Long-Term Investments	0	0	-6.18M	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	6.18M	0	0	0	0	0	0	0
Total Assets+	13.83M	39.51M	52.2M	29.64M	25.01M	4.1M	26.72M	19.55M	4.3M	3.08M
Asset Turnover	1.15x	0.91x	0.93x	1.45x	1.60x	-	-	-	-	-
Asset Growth %	2719.73%	1.86%	0.32%	-0.43%	-0.16%	-0.84%	5.52%	-0.27%	-0.78%	-0.28%
Total Current Liabilities+	8.58M	12.71M	30.37M	14.69M	14.38M	681.25K	2.08M	4M	2.34M	1.49M
Accounts Payable	2.6M	5.13M	5.32M	4.38M	4.7M	681.25K	683.39K	463.27K	1.22M	521.75K
Days Payables Outstanding	92.71	63.25	50.67	46.98	53.97	2.06K	365.95	388.55	1.09K	564.28
Short-Term Debt	1.24M	3.49M	4.8M	5.21M	4.88M	0	0	0	0	0
Deferred Revenue (Current)	44.84K	0	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	3K	564.24K	20.24M	3.8M	737.79K	0	0	1.76M	350.72K	3.09K
Current Ratio	0.84x	0.79x	0.48x	0.68x	0.53x	3.35x	8.51x	4.61x	1.53x	1.84x
Quick Ratio	0.84x	0.79x	0.48x	0.68x	0.53x	3.35x	8.51x	4.61x	1.53x	1.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	15.14M	2.38M	4.19M	0	0	2.33M	0	0	0
Long-Term Debt	5M	1.54M	2.38M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	68.86K	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	13.6M	0	4.19M	0	0	2.26M	0	0	0
Total Liabilities	13.58M	27.84M	32.75M	18.88M	14.38M	681.25K	4.41M	4M	2.34M	1.49M
Total Debt+	6.24M	5.03M	7.18M	5.21M	4.88M	0	176.3K	63.82K	0	0
Net Debt	4.36M	3.65M	2.3M	3.84M	4.45M	-1.58M	-17.18M	-17.66M	-2.29M	-2.24M
Debt / Equity	24.12x	0.43x	0.37x	0.48x	0.46x	-	0.01x	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.84x	-7.16x	-20.82x	-9.79x	-9.15x	-12.62x	-2514.98x	-3802.90x	-4435.93x	-
Total Equity+	258.53K	11.66M	19.44M	10.76M	10.62M	3.42M	22.31M	15.56M	1.96M	1.59M
Equity Growth %	67.79%	44.11%	0.67%	-0.45%	-0.01%	-0.68%	5.53%	-0.3%	-0.87%	-0.19%
Book Value per Share	1397.48	53503.22	77779.20	27169.44	4821.40	356.20	566.69	89.83	10.87	38.01
Total Shareholders' Equity	258.53K	11.66M	19.44M	10.76M	10.62M	3.42M	22.31M	14.67M	1.96M	1.59M
Common Stock	118.74K	138.86K	181.63K	423.29K	25.22K	100.95K	6.52K	20.78K	27.39K	6.78K
Retained Earnings	-1.05M	-3.83M	-15M	-34.48M	-40.51M	-11.76M	-60.74M	-79.21M	-96.5M	-106.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-7.43K	36.88K	87K	60.01K	-181.28K	-30.8K	-536.73K	-569.75K	-594.52K
Minority Interest	0	3.38K	0	0	0	0	0	885.03K	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.67M	-2.7M	-2.74M	-2.57M	-647.86K	-3.89M	-11.46M	-17.15M	-14.09M	-7.73M
Operating CF Margin %	-0.23%	-0.07%	-0.06%	-0.06%	-0.02%	-	-	-	-	-
Operating CF Growth %	-84.06%	0.26%	-0.01%	0.06%	0.75%	-5%	-1.95%	-0.5%	0.18%	0.45%
Net Income	-1.89M	-2.78M	-11.16M	-16.9M	-2.41M	-6.86M	-48.98M	-18.47M	-17.29M	-9.57M
Depreciation & Amortization	157.94K	1.36M	3.22M	2.9M	0	120.87K	681.61K	435.2K	408.03K	337.49K
Stock-Based Compensation	0	1.46M	7.08M	1.25M	0	1.98M	12.6M	2.62M	2.15M	1.56M
Deferred Taxes	0	-3.49M	-2.39M	6.35M	0	0	-7.45M	-1.5M	0	0
Other Non-Cash Items	552.62K	528.39K	1.06M	4.86M	738.5K	1.25M	30.51M	-9.3K	813.88K	372.21K
Working Capital Changes	-2.49M	218.45K	-539.78K	-1.03M	1.02M	-369.5K	1.19M	-217.66K	-174.75K	-423.24K
Change in Receivables	-2.3M	-3.19M	-778.54K	967.03K	1.49M	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	3.6M	620.79K	-2.1M	222.68K	0	383.2K	263.69K	-103.85K	-834.63K
Cash from Investing+	-1.51M	-6.59M	-808.88K	-3.64M	0	-44.14K	2.19M	-584.16K	11.67K	0
Capital Expenditures	-1.69M	-3.69M	-4.84K	0	0	-44.14K	-864.72K	-584.16K	-5.18K	0
CapEx % of Revenue	0.11%	0.1%	0%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-2.9B	-804.04K	6.42K	0	0	-675	-958.04K	16.85K	0
Cash from Financing+	6.24M	8.8M	7.05M	2.69M	560K	5.53M	24.9M	18.18M	-1.34M	7.67M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-2.09B	-2.09T	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	3.38K	2.09B	-1.66M	22K	3.37M	3.29M	958.04K	-291.08K	4.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.36M	-6.39M	-2.75M	-2.57M	-647.86K	-3.93M	-12.32M	-17.73M	-14.1M	-7.73M
FCF Margin %	-0.34%	-0.18%	-0.06%	-0.06%	-0.02%	-	-	-	-	-
FCF Growth %	-123.12%	-0.19%	0.57%	0.07%	0.75%	-5.07%	-2.13%	-0.44%	0.2%	0.45%
FCF per Share	-28960.57	-29325.62	-10982.54	-6478.52	-294.08	-410.15	-313.05	-102.38	-78.37	-184.36
FCF Conversion (FCF/Net Income)	1.94x	0.97x	0.30x	0.15x	0.12x	0.57x	0.23x	0.93x	815.10x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	9.51K	5K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1484.92%	-46.65%	-58.34%	-111.89%	-52.42%	-97.81%	-380.82%	-97.74%	-0.2%	-539.57%
Return on Invested Capital (ROIC)	-60.9%	-40.49%	-48.45%	-29.5%	-31.98%	-49.83%	-558.88%	-990.44%	-	-
Gross Margin	36%	18.08%	21.07%	20.89%	20.42%	-	-	-	-	-
Net Margin	-11.83%	-7.69%	-18.67%	-39.3%	-14.04%	-	-	-	-	-
Debt / Equity	24.12x	0.43x	0.37x	0.48x	0.46x	-	0.01x	0.00x	-	-
Interest Coverage	-7.84x	-7.16x	-20.82x	-9.79x	-9.15x	-12.62x	-2514.98x	-3802.90x	-4435.93x	-
FCF Conversion	1.94x	0.97x	0.30x	0.15x	0.12x	0.57x	0.23x	0.93x	815.10x	0.81x
Revenue Growth	-	126.24%	34.44%	-11.51%	-7.17%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Enveric Biosciences, Inc. (ENVB) grew revenue by 0.0% over the past year. Growth has been modest.

Enveric Biosciences, Inc. (ENVB) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Enveric Biosciences, Inc. (ENVB) has a return on equity (ROE) of -539.6%. Negative ROE indicates the company is unprofitable.

Enveric Biosciences, Inc. (ENVB) had negative free cash flow of $7.7M in fiscal year 2024, likely due to heavy capital investments.